Biomarker hub
PD-L1
Trials and papers mentioning PD-L1.
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
RECRUITING · Phase not listed
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
RECRUITING · Phase not listed
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
ACTIVE_NOT_RECRUITING · Phase not listed
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
RECRUITING · Phase not listed
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RECRUITING · Phase not listed
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
ACTIVE_NOT_RECRUITING · Phase not listed
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE_NOT_RECRUITING · Phase not listed
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
RECRUITING · Phase not listed
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
ACTIVE_NOT_RECRUITING · Phase not listed
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
ACTIVE_NOT_RECRUITING · Phase not listed
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE_NOT_RECRUITING · Phase not listed
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
ACTIVE_NOT_RECRUITING · Phase not listed
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RECRUITING · Phase not listed
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase not listed
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
ACTIVE_NOT_RECRUITING · Phase not listed
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
SUSPENDED · Phase not listed
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITING · Phase not listed
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary.
Journal of medical economics · 12/1/2026
Digital spatial profiling of α-PD-1 treated breast cancer bone metastases reveals region-specific signaling and enrichment of immune-suppressive markers.
Journal of bone oncology · 4/1/2026
Ultrasound-triggered carrier-free nanoprodrugs activate cGAS-STING pathway to enhance tumor-targeting chemo-immunotherapy.
Materials today. Bio · 4/1/2026
Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.
JHEP reports : innovation in hepatology · 3/1/2026
A multicenter multimodel habitat radiomics model for predicting immunotherapy response in advanced NSCLC.
iScience · 2/20/2026
TLR7-mediated inflammation drives PD-L1 upregulation and T cell exhaustion during influenza A virus infection.
iScience · 2/20/2026
Immune Checkpoint Inhibitors for the Treatment of Periorbital Non-Melanoma Skin Cancers.
Seminars in ophthalmology · 2/18/2026
Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
Oncogene · 2/17/2026
Curcumin enhances GSDME-mediated pyroptosis to potentiate PD-1/PD-L1 immune checkpoint blockade in colorectal cancer.
Frontiers in pharmacology · 1/1/2026
Deer antler stem cell-derived exosomes: a regenerative medicine powerhouse from nature's own repair kit.
Frontiers in cell and developmental biology · 1/1/2026
Evaluating the Relationship Between Programmed Death Ligand-1 (Clone: 22C3), Anaplastic Lymphoma Kinase (D5F3), and C-ros Oncogene 1 (OT11A1) Expression in Lung Adenocarcinoma.
Cureus · 1/1/2026
Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastases in penile cancer.
Frontiers in immunology · 1/1/2026
Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response
cancer biology · 4/17/2025
BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma
cancer biology · 4/1/2025
Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and Copper
oncology · 2/24/2025
VNAR: shark single-domain antibodies for the new era of medical biotechnology.
Frontiers in immunology · 1/1/2025